Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour

Core Insights - Embecta's end market growth is influenced by new technologies that are capturing market share in insulin delivery, alongside the rising use of GLP-1 drugs which are reducing the frequency of Embecta's product usage [1] Company Analysis - Embecta is facing competition from emerging technologies in the insulin delivery market, which may impact its market share [1] - The increased adoption of GLP-1 drugs is leading to a decline in the frequency of Embecta's product usage, indicating a shift in treatment preferences among patients [1]